Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jack Wahlen

Endocrinology, Diabetes & Metabolism Ogden, UT Medical Doctor

NPI 1033143508 CMS profile 364140

4403 Harrison Blvd, Ste 3630, Ogden, UT 84403

Open in the dashboard

General payments

$69,675

57 records reported · program years 2019–2025

Research payments

$1,394

Paid to them · 12 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,388,550 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Jack Wahlen of Ogden, UT is reported in the CMS Open Payments database as having received $69,675 across 57 general payments and $1,394 in research payments paid to them. Separately, studies naming them as principal investigator received $1,388,550 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 92nd percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,361 10
2024 General $16,537 7
2022 General $32 1
2022 Research $163 1
2021 General $15,335 12
2020 General $7,404 7
2019 General $20,005 20
2019 Research $1,231 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jack Wahlen
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Jack Wahlen were reported at $10,361. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Jack Wahlen Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $20,005 $494 $123–$2,253 $163
2020 $7,404 $335 $85–$1,841 $114
2021 $15,335 $398 $88–$1,981 $132
2022 $32 $364 $88–$1,568 $149
2023 $0 $420 $113–$1,614 $160
2024 $16,537 $440 $121–$1,646 $164
2025 $10,361 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sanofi-Aventis U.S. LLC $67,814 48 payments
  2. AbbVie, Inc. $1,761 5 payments
  3. Novo Nordisk Inc $65 2 payments
  4. AstraZeneca Pharmaceuticals LP $18 1 payment
  5. Lilly USA, LLC $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $57,755 29 payments
  2. Travel and Lodging $10,913 4 payments
  3. Food and Beverage $861 21 payments
  4. Education $147 3 payments
Products named General payments · program years 2019–2025
  1. TOUJEO Diabetes $10,688 8 payments
  2. SOLIQUA 100/33 Diabetes $9,282 10 payments
  3. SOLIQUA 100/33 Endocrine & Metabolic Diseases $7,329 5 payments
  4. TZIELD $6,174 7 payments
  5. TOUJEO Endocrine & Metabolic Diseases $5,174 4 payments
  6. SOLIQUA 100/33 Endocrinology $1,272 2 payments
  7. TOUJEO Endocrinology $848 1 payment
  8. SOTAGLIFLOZIN $22 1 payment
  9. DIABETES - DISEASE $22 1 payment
  10. EFPEGLENATIDE $22 1 payment
  11. Other $17 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. AbbVie, Inc. $1,231 11 payments
  2. Eli Lilly and Company $163 1 payment

Records

69 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record